FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 696 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Connecting and Celebrating December 23, 2020 Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 Load more HOT NEWS Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection How I Navigated Being a Young Mom During Cancer: A Survivor’s... First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer...
